[
  {
    "ts": null,
    "headline": "Biogen: Jefferies confirms its target as it awaits Ocrevus",
    "summary": "Jefferies confirms its Buy rating on Biogen shares, with an unchanged price target of $250. The analyst reports that crucial data from a Phase III trial of Ocrevus could arrive in the first half of...",
    "url": "https://finnhub.io/api/news?id=f15801c358037b3c29a73a3cb9d4f440a34d1e94ffb5ad4366758cdc435176ad",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732534515,
      "headline": "Biogen: Jefferies confirms its target as it awaits Ocrevus",
      "id": 131625257,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Jefferies confirms its Buy rating on Biogen shares, with an unchanged price target of $250. The analyst reports that crucial data from a Phase III trial of Ocrevus could arrive in the first half of...",
      "url": "https://finnhub.io/api/news?id=f15801c358037b3c29a73a3cb9d4f440a34d1e94ffb5ad4366758cdc435176ad"
    }
  }
]